COMMITTED TO DISCOVERING BEST-IN-CLASS ORAL THERAPIES
TO CONQUER CANCER AND INFLAMMATORY DISEASE

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and allergic inflammatory diseases. Utilizing our proprietary drug discovery and development engine, we develop highly selective small molecules that are designed to modulate critical immune responses underlying these diseases. Since our founding, we have discovered and advanced two drug candidates each uniquely targeting CCR4, including our lead oncology drug candidate, FLX475, in clinical development, and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019.
We are also pursuing a range of targets, including GCN2 and HPK1, that are in earlier stages of discovery and development. We believe our unwavering focus, applying scientific rigor and discipline to advance oral treatments that intelligently target key drivers of the immune system, allows us to combat cancer and allergic diseases and, importantly, improve patients’ lives.